Comparative Pharmacology
Head-to-head clinical analysis: PEPCID AC versus PEPCID PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID AC versus PEPCID PRESERVATIVE FREE.
PEPCID AC vs PEPCID PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, inhibiting gastric acid secretion.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
20 mg intravenously over at least 2 minutes or as an infusion over 15-30 minutes every 12 hours; alternatively, 20 mg orally once or twice daily.
None Documented
None Documented
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
2.5-3.5 hours (normal renal function); prolonged to 20-30 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: dose adjustment required in renal insufficiency.
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Renal (65-70% unchanged by tubular secretion); minor biliary/fecal elimination (<30%). Clearance correlates with creatinine clearance.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist